Evotec SE · ISIN: DE0005664809 · EQS - Company News

Strategic Progress and Successful Expansion Amid Challenging Market Conditions

Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships  Successful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutions Priority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and s...

XETR:EVT Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Evotec SE

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (42)
Short Selling (DE) (35)
Short Selling (UK) (0)
06 November 2024 07:00AM
Strategic Progress and Successful Expansion Amid Challenging Market Conditions
DE0005664809
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships  Successful extensions & expansions with BMS and Novo Nordisk; new collaboration...
Evotec SE
About the publication
05 November 2024 07:29AM
Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
DE0005664809
  Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners Transaction aligns with Evotec’s strategic optimization efforts, concentrating resources on key growth drivers New ownership committed to maintaining and growing the business   Hamburg, 05 November 2024: Evotec SE (Frankfur...
Evotec SE
About the publication
30 October 2024 08:10AM
Evotec SE to announce results for the first nine months 2024 on 06 November 2024
DE0005664809
Hamburg, Germany, 30 October 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024. The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing ...
Evotec SE
About the publication
23 October 2024 07:29AM
Evotec and Bristol Myers Squibb expand proteomics partnership
DE0005664809
  Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value   Hamburg, Germany, 23 October 2024: Evotec SE (Frankfurt Stock Exchange: EV...
Evotec SE
About the publication
26 September 2024 07:30AM
Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies
DE0005664809
  Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies   Hamburg, Germany, 26 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Evotec has entered a techn...
Evotec SE
About the publication
20 September 2024 03:29PM
Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
DE0005664809
  J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions   Hamburg, Germany, and Toulouse, France, 20 Septemb...
Evotec SE
About the publication
20 September 2024 03:29PM
Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
DE0005664809
  J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions   Hamburg, Germany, and Toulouse, France, 20 Septemb...
Evotec SE
About the publication
03 September 2024 07:30AM
Evotec announces change in Management Board
DE0005664809
  Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024 Distribution of responsibilities across other Management Board functions   Hamburg, Germany, 03 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Business Officer, ...
Evotec SE
About the publication
14 August 2024 07:00AM
Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths
DE0005664809
  Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery – higher share of integrated long-term deals will improve revenue contribution beyond 2024 Strong progress of Just – Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity r...
Evotec SE
About the publication
13 August 2024 07:30AM
Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
DE0005664809
  Key scientific achievements drive the expansion of the pipeline of molecular glue degraders Performance-based and programme-based payments of in total US$ 75 m to Evotec   Hamburg, Germany, 13 August 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced further strong progr...
Evotec SE
About the publication
08 August 2024 07:30AM
Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
DE0005664809
  Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research   Hamburg, Germany, 08 August 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership wit...
Evotec SE
About the publication
07 August 2024 01:00PM
Evotec SE reports first half-year 2024 results on 14 August 2024
DE0005664809
  Hamburg, Germany, 07 August 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The con...
Evotec SE
About the publication
06 August 2024 09:07PM
Evotec provides guidance update
DE0005664809
  Navigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just – Evotec Biologics with mid double-digit revenue growth versus strong comparable basis Adjusted EBITDA impacted by high fixed cost base in Shared R&D and ramp-up costs for J.POD Toulouse, France Further strengthened sales order book i...
Evotec SE
About the publication
06 August 2024 09:04PM
Evotec SE provides guidance update
DE0005664809
Ad hoc: Evotec SE provides guidance update Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its guidance for the fiscal year 2024. The Company expects Group revenues in the range of € 790 – 820 m (low to mid-single-digit percent...
Evotec SE
About the publication
10 July 2024 07:30AM
Evotec and Pfizer collaborate to advance drug discovery in France
DE0005664809
  Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases   Hamburg, Germany, 10 July 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced it has entered into a multi-year master research collaboration and option and licens...
Evotec SE
About the publication
08 July 2024 02:00PM
Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
DE0005664809
  Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term commercial supply security   Hamburg, Germany, and Seattle, WA, USA, 8 July 2024: Evotec SE ...
Evotec SE
About the publication
25 June 2024 07:30AM
Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
DE0005664809
  Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD’s Manufacturing Optimization Program Manufacturing solution includes seamless integration of accelerated mAb drug development into the overall Manufacturing Optimization Program Manufacturing Optimization P...
Evotec SE
About the publication
12 June 2024 07:30AM
Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
DE0005664809
  Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research   Hamburg, Germany, 12 June 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today th...
Evotec SE
About the publication
10 June 2024 06:00PM
Results of the Annual General Meeting 2024
DE0005664809
  Most agenda items adopted with great majority Annual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario Polywka   Hamburg, Germany, 10 June 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced...
Evotec SE
About the publication
30 May 2024 07:30AM
Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases
DE0005664809
  Partnership will expand Evotec’s molecular patient database in the area of metabolic diseases and in particular obesity Evotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomics Lille University Hospital will provide human biological samp...
Evotec SE
About the publication
30 May 2024 07:30AM
Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases
DE0005664809
  Partnership will expand Evotec’s molecular patient database in the area of metabolic diseases and in particular obesity Evotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomics Lille University Hospital will provide human biological samp...
Evotec SE
About the publication
28 May 2024 07:30AM
Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease
DE0005664809
  Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington’s disease One of Evotec’s largest strategic drug discovery alliances   Hamburg, Germany, 28 May 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has announced the extension of its 20...
Evotec SE
About the publication
28 May 2024 07:30AM
Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease
DE0005664809
  Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington’s disease One of Evotec’s largest strategic drug discovery alliances   Hamburg, Germany, 28 May 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has announced the extension of its 20...
Evotec SE
About the publication
22 May 2024 07:00AM
Evotec reports Q1 2024 results and provides corporate update
DE0005664809
CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTER STRONG START WITH JUST – EVOTEC BIOLOGICS IN Q1 2024 POSITIVE MOMENTUM IN SHARED R&D DISCOVERY CLOSED SALES POINT TO RECOVERY OF REVENUES TOWARDS END OF THE YEAR RESET FOR PROFITABLE GROWTH INITIATED, NEW REPORTING SEG...
Evotec SE
About the publication
15 May 2024 12:00PM
Evotec SE to announce results for first quarter 2024 on 22 may 2024
DE0005664809
Hamburg, Germany, 15 May 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first quarter of 2024 on Wednesday, 22 May 2024. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call...
Evotec SE
About the publication
30 April 2024 08:30AM
Bayer and Evotec collaborate to advance precision cardiology
DE0005664809
BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS JOINT EFFORT AIMS TO DEVELOP INNOVATIVE THERAPIES IN PRECISION CARDIOLOGY   Berlin and Hamburg, Germany, 30 April 2024: Bayer and the German-based l...
Evotec SE
About the publication
24 April 2024 07:00AM
Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth
DE0005664809
FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M EVOTEC’S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D” AND “JUST – EVOTEC BIOLOGICS” STARTING Q1 2024 Hamburg, Germany, 24 April 202...
Evotec SE
About the publication
23 April 2024 08:40PM
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
DE0005664809
Hamburg, Germany, 23 April 2024: The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has appointed Dr Christian Wojczewski as the Company’s new Chief Executive Officer (“CEO”), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that bega...
Evotec SE
About the publication
23 April 2024 08:38PM
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
DE0005664809
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces the appointment of Dr Christian Wojczewski as Chief Executive Officer of the Company, effective 01 July 2024. Dr Wojczewski holds a degree in chemistry and has over 20 years of experience in various man...
Evotec SE
About the publication
18 April 2024 01:27PM
Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments
DE0005664809
  COLLABORATION LEVERAGES VARIANT BIO’S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC’S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL SUCCESS OF THE PROGRAMM...
Evotec SE
About the publication
17 April 2024 03:00PM
Evotec SE to announce results for fiscal year 2023 on 24 April 2024
DE0005664809
Hamburg, Germany, 17 April 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in ...
Evotec SE
About the publication
17 April 2024 07:30AM
Evotec welcomes Aurélie Dalbiez as Chief People Officer
DE0005664809
Hamburg, Germany, 17 April 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the appointment of Aurélie Dalbiez as the Company’s new Chief People Officer (“CPO”), effective 15 June 2024. Aurélie will be joining Evotec’s Management Board, bringing with her a wealth of experience and experti...
Evotec SE
About the publication
06 March 2024 07:30AM
Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinic
DE0005664809
CLARIS’S PORTFOLIO COMPANIES RECEIVE EASY ACCESS TO EVOTEC’S FULL RANGE OF PRE-CLINICAL AND CLINICAL DEVELOPMENT AND MANUFACTURING CAPABILITIES AGREEMENT BUILDS ON SUCCESSFUL COLLABORATION BETWEEN EVOTEC AND CLARIS’S PORTFOLIO COMPANY IAMA   Hamburg, Germany, and Turin, Italy, 06 March 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ...
Evotec SE
About the publication
07 February 2024 07:30AM
Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV
DE0005664809
JUST – EVOTEC BIOLOGICS TO PROVIDE DEVELOPMENT AND PHASE I CLINICAL MANUFACTURING OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV  AGREEMENT BUILDS ON PREVIOUS NIAID-FUNDED COLLABORATION TO DEVELOP A BROADLY NEUTRALISING ANTIBODY AGAINST HIV Hamburg, Germany, 07 February 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;...
Evotec SE
About the publication
22 January 2024 07:30AM
Invitation to Conference Call
DE0005664809
Hamburg, Germany, 22 January 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024. During the call, the Chairwoman of Evotec’s Supervisory Board, Prof. Iris Löw-Friedrich and Evotec’s CEO Dr Mari...
Evotec SE
About the publication
10 January 2024 03:30PM
Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies
DE0005664809
EVOTEC JOINS FORCES WITH THE CROHN’S & COLITIS FOUNDATION’S IBD THERAPEUTICS INCUBATOR TO ADVANCE DRUG DISCOVERY AND IDENTIFY NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE (“IBD”) THE COLLABORATION LEVERAGES EVOTEC'S END-TO-END INTEGRATED R&D PLATFORM TO ADVANCE DRUG DISCOVERY FOR TWO INNOVATIVE DRUG TARGETS ADDRESSING FIBROSIS AND IMPAIR...
Evotec SE
About the publication
08 January 2024 07:30AM
Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
DE0005664809
KEY SCIENTIFIC ACHIEVEMENT ADVANCES THE JOINT NEUROSCIENCE PIPELINE AND EARNS A PAYMENT OF US$ 25 M TO EVOTEC TO PROGRESS FURTHER RESEARCH   Hamburg, Germany, 08 January 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myer...
Evotec SE
About the publication
04 January 2024 07:30AM
Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I
DE0005664809
PARTNERSHIP COMBINES OWKIN’S A.I. TARGET DISCOVERY CAPABILITIES WITH EVOTEC’S INTEGRATED END-TO-END SHARED R&D PLATFORM A.I.-POWERED PLATFORMS WILL ACCELERATE OWKIN’S NOVEL PROGRAMMES FROM THE DISCOVERY PHASE TO THE CLINIC AGREEMENT INCLUDES SUCCESS-BASED MILESTONES AND ROYALTY PAYMENTS TO EVOTEC  Hamburg, Germany, and Paris, France, 04 Janu...
Evotec SE
About the publication
03 January 2024 06:25PM
Evotec announces CEO transition
DE0005664809
DR WERNER LANTHALER TO STEP DOWN AS CEO REMAINS AVAILABLE AS STRATEGIC ADVISOR TO THE SUPERVISORY BOARD TO FACILITATE A SMOOTH TRANSITION DR MARIO POLYWKA HAS AGREED TO STEP IN AS INTERIM CEO SEARCH STARTED FOR PERMANENT CEO TO CONTINUE BUILDING THE GLOBALLY LEADING COMPANY FOR EXTERNAL INNOVATION EVOTEC CONFIRMS GUIDANCE 2023 Hamburg, Germany...
Evotec SE
About the publication
03 January 2024 06:24PM
Evotec announces CEO transition
DE0005664809
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to serve until the end of his current term, for personal reasons. The Supervisory Bo...
Evotec SE
About the publication
19 December 2023 07:30AM
Evotec receives US$ 2.5 m grant to leverage human iPSC-derived teratogenicity platform for global health programmes
DE0005664809
EVOTEC JOINS THE BILL & MELINDA GATES FOUNDATION FUNDED GLOBAL HEALTH DISCOVERY COLLABORATORY (“GHDC”) AS A NEW ADDITION TO THE FIFTEEN COLLABORATORY PLATFORMS GRANT FROM THE BILL & MELINDA GATES FOUNDATION PROVIDES GHDC MEMBER INSTITUTIONS WITH ACCESS TO EVOTEC’S IPSC-DERIVED HIGH-THROUGHPUT TERATOGENICITY PLATFORM   Hamburg, Germany, 19...
Evotec SE
About the publication
14 December 2023 07:30AM
Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases
DE0005664809
GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF ANCA-ASSOCIATED VASCULITIS CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN WILL COLLECT BIOSAMPLES FROM ANCA-ASSOCIATED VASCULITIS PATIENTS EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECHNOLOGIES TO IMPROVE PATIENT STRATIFICATION AND CREATE NEW ENTRY POINTS FOR PRECISION MEDICINE...
Evotec SE
About the publication
06 December 2023 07:30AM
Evotec-partner Jingxin receives approval for EVT201 in China
DE0005664809
EVT201 APPROVED BY THE CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (“NMPA”) AS A NOVEL SHORT-TERM TREATMENT OF INSOMNIA EVOTEC’S LICENCE PARTNER ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD (“JINGXIN”) WILL LEAD ALL COMMERCIALISATION EFFORTS FOR EVT201 IN CHINA AND SOUTH KOREA   Hamburg, Germany, 06 December 2023: Evotec SE (Frankfurt Stock Exc...
Evotec SE
About the publication
15 November 2023 07:30AM
Evotec presents precision medicine platforms for accelerated pipeline building at Capital Markets Day
DE0005664809
PRECISION MEDICINE CAPABILITIES SHAPING (NEW) MARKETS WITH FIRST-IN-CLASS THERAPEUTICS PANOMICS, IPSC & A.I./M.L. PLATFORMS ARE THE STEP CHANGE FOR GROWTH AND ACCELERATED PIPELINE BUILDING CONFIRMATION OF ACTION PLAN 2025 GOALS AND PROGRESS UPDATE Hamburg, Germany, 15 November 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN...
Evotec SE
About the publication
08 November 2023 07:00AM
Evotec SE reports results for the first nine months 2023 and provides corporate update
DE0005664809
CONTINUATION OF STRONG GROWTH IN DEMANDING MARKETS PARADIGM-SHIFTING OFFERINGS ARE STRONGEST GROWTH DRIVERS PIPELINE PROGRESS, E.G. WITH ADVANCED ASSET IN NEURODEGENERATION ALL ELEMENTS OF GUIDANCE CONFIRMED   Hamburg, Germany, 08 November 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announc...
Evotec SE
About the publication
07 November 2023 07:30AM
Evotec and Dewpoint Therapeutics enter strategic partnership in oncology
DE0005664809
STRATEGIC PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMMES TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC’S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORM AGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILESTONE AND ROYALTY PAYMENTS TO EVOTEC BASED ON SUCCESS OF OVER...
Evotec SE
About the publication
01 November 2023 12:05PM
Evotec SE to announce results for the first nine months 2023 on 08 November 2023
DE0005664809
Hamburg, Germany, 01 November 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first nine months 2023 on Wednesday, 08 November 2023. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conf...
Evotec SE
About the publication
05 October 2023 07:30AM
Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'
DE0005664809
  A UNIQUE COMPANY CREATION VEHICLE INITIATED BY LIGHTSTONE VENTURES AND EVOTEC SE, AND ESTABLISHED WITH PARTNERS CLAVYSTBIO, LEAPS BY BAYER, POLARIS PARTNERS, AND THE POLARIS INNOVATION FUND FIRST-OF-ITS-KIND PARTNERSHIP IN SINGAPORE AND ASIA LEVERAGES BREAKTHROUGH SCIENCE FROM RESEARCHERS AT AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (“A*STAR”...
Evotec SE
About the publication
More Evotec SE related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 42 1st October 2024 Rouxel, Laetitia DD
Short Seller (DE) 35 4th November 2024 PDT Partners, LLC SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN